Titan pharmaceuticals inc (TTNP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss

-5,584

-3,941

-2,803

-5,197

-4,517

-3,504

-2,045

-869

-2,605

-3,660

-4,191

-3,451

-3,005

-2,327

-2,620

11,928

-1,846

-2,294

-1,807

-2,281

-4,897

-473

716

-842

-1,804

-209

-1,145

5,064

6,001

-279

-8,014

-1,724

-5,163

-2,898

-804

-6,989

-4,512

Adjustments to reconcile loss to net cash used in operating activities:
Depreciation and amortization

62

58

63

63

60

43

113

112

112

109

105

102

101

98

93

93

93

93

88

88

89

88

89

88

88

88

7

7

5

4

4

4

5

6

7

9

10

Non-cash interest expense

148

146

132

166

169

159

123

123

85

141

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash gain on termination of royalty purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

17,924

0

0

-8,962

-

-

-

-

-

-

-

-

Amortization of discount on long-term debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

248

489

489

294

Interest on royalty liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

373

167

-

-

-

-

Non-cash loss on changes in fair value of warrants

923

-

-

-

0

-

-

-

-

-

-2

-190

-422

-

5

110

-4

-

-

-

-

-

-1,461

284

864

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash gain on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-46

-2

-1,185

-3,279

-

-

-

-

0

0

0

1,860

-

-

-

-

-

-

-

-

Non-cash (gain) loss on changes in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,011

5,362

-3,045

-

-3,673

1,955

-16

-

-

-

-

Stock-based compensation

-84

-42

128

350

136

335

388

402

432

480

404

382

421

256

202

249

332

367

92

76

491

86

71

60

326

22

21

130

505

348

365

316

1,552

369

239

430

139

Finance costs attributable to issuance of warrants

211

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Receivables

558

218

-365

-912

315

1,055

493

162

-38

-26

4

-922

-2,578

-2,321

1,057

-6

644

315

-578

993

-485

-175

400

-337

-738

228

739

-243

-552

1,116

-380

379

-189

923

1,066

-424

930

Inventory

66

-

-

71

-16

-

-

1,317

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract assets

0

-

-

0

-99

-

-

0

72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contract assets

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other assets

399

55

295

-138

335

4

122

-184

243

85

-40

-116

196

-41

41

-133

196

-88

24

-58

151

-122

51

-71

83

-58

59

-62

-422

-101

-17

-93

62

-63

-29

708

-74

Accounts payable

-64

-14

390

-175

-326

430

358

230

-476

691

103

-401

-2,587

-3,008

650

988

227

147

-691

705

-411

-

-

-

-

-153

924

-1,758

2,338

-1,661

-740

615

764

1,484

176

-2,145

2,817

Accrued sales allowances

-608

59

-80

-57

887

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other accrued liabilities

810

-

-

-300

145

-

-

-89

321

-

-

-

-

-

-

-

-

-

-

-

-

822

552

-427

-775

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

0

0

0

0

-313

-313

-313

-470

1,409

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other

3

-221

270

-22

14

134

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

0

0

-760

-911

-912

-911

-912

-911

-911

-2,199

-2,198

-3,750

-

-

-

-

-

-

-

-

Net cash provided by (used in) operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,507

-2,038

-

-1,762

-1,922

-2,026

-1,572

-1,395

-1,341

-1,557

-2,104

-2,179

-3,812

-1,704

-

-

-

-

-

-

-

-

Net cash used in operating activities

-5,212

-3,663

-3,325

-4,149

-4,308

-3,308

-2,268

-1,856

-999

-3,502

-3,545

-2,520

-3,110

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,377

-2,657

-2,532

-

-3,320

-6,860

-2,108

Cash flows from investing activities:
Purchases of property and equipment

30

112

61

39

44

345

18

-5

58

20

129

0

26

75

48

-9

57

77

47

2

7

0

8

8

2

21

-1

118

180

32

133

467

522

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

-57

-

-47

-2

-7

0

-8

-8

-2

-21

1

-118

-180

-

-

-

-

-

-

-

-

Net cash used in investing activities

-30

-112

-61

-39

-44

-345

-18

5

-58

-20

-129

0

-26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-133

-467

-522

-

-

-

-

Cash flows from financing activities:
Net proceeds from equity offerings

1,895

-

2,001

466

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock from the exercise of stock options

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

113

-

-

-

-

-

-

-

-

Issuance of common stock from the vesting of restricted shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net proceeds from the exercises of common stock warrants

6,162

879

14

105

605

3,268

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,275

-

-

-

-

-

-

-

-

Payments of long-term debt

-

-

-

-

-

0

0

0

3,000

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

258

45

46

44

0

0

7,292

272

Issuance of common stock due to the vesting of restricted shares

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-14

9,592

0

-37

0

4,925

0

-2,500

1,388

-

-

-

-

-

-

-

-

Net cash provided by financing activities

8,057

8,077

2,015

571

605

4,521

9,099

0

-3,000

-283

7,012

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,468

4,920

-44

-

0

12,208

-272

Net decrease in cash and cash equivalents

2,815

-

-

-

-3,747

-

-

-

-4,057

-

-

-2,520

-3,136

-2,483

-2,816

13,543

-2,095

-1,833

-1,809

-1,924

-2,047

8,020

-1,403

-1,386

-1,559

2,800

-2,178

-6,430

-496

13,040

958

1,796

-3,098

2,634

-3,320

5,292

-2,380

Supplemental disclosure of cash flow information:
Interest paid

102

104

109

110

109

127

110

111

123

174

124

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Warrants issued

-

-

-

-

-

-

-

-

470

0

287

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable

6

-

-

-

3

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-